Pancreatic exocrine neoplasm

This trial tests a personalized therapy called GT201, made from a patient's own tumor-infiltrating lymphocytes (TILs). The goal is to see if these immune cells, grown in the lab and infused back into the patient, can shrink or eliminate advanced solid tumors. The study includes a…

This study tests a personalized cancer vaccine (ABO2109) combined with an immunotherapy drug (toripalimab) in 50 adults with solid tumors. The goal is to see if the vaccine is safe and triggers an immune response against the cancer. Participants must have good organ function and …

This trial is testing an investigational drug called SHR-8203, given as an injection, in people with advanced or metastatic solid tumors that have not responded to standard treatments or for which no standard treatment exists. The study aims to find the safest dose, understand ho…

This study tests an experimental drug called ATX-898 in people with advanced solid tumors that have spread or cannot be removed by surgery. The trial has two parts: first, ATX-898 is given alone to find the safest dose; second, it is combined with other anti-cancer drugs to see i…

This early-stage trial tests a drug called samuraciclib in 15 people with localized pancreatic cancer that can be surgically removed. Participants will take the drug for about two weeks before their planned surgery. Researchers will check safety and look for changes in tumor cell…

This phase 2 trial is testing whether combining two immunotherapy drugs—vilastobart and retifanlimab—can shrink tumors in people with metastatic pancreatic cancer that has a BRCA1, BRCA2, or PALB2 gene mutation. Participants receive both drugs by IV infusion over several months. …

This early-stage trial tests an experimental oral drug called SNV1521, a PARP inhibitor, combined with the RAS-targeting medicine daraxonrasib in adults with pancreatic cancer that cannot be surgically removed or has spread. The main goals are to find safe and tolerable doses of …

This early-stage trial is testing an investigational drug called BR113 in people with advanced solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety, find the right dose, and see if it can shrink tumors. Participants receive BR…

This phase II trial tests whether choosing chemotherapy based on a specific gene mutation (SMAD4) can improve outcomes for people with pancreatic cancer that is or may be surgically removable. The SMAD4 gene normally acts as a brake on tumor growth, but when it's mutated, tumors …

This early-stage trial is testing an experimental drug called TQB6426 in people with advanced cancers that have not responded to other treatments. TQB6426 is designed to seek out a protein called GPC3 on cancer cells and deliver a chemotherapy-like payload directly to them. The s…

This early-stage trial tests a personalized cell therapy for adults with advanced solid tumors that have not responded to standard treatments. Doctors take immune cells from a patient's own tumor, grow more of them in the lab, and then infuse them back after a short course of che…

This trial investigates a new drug called GEN1119 for people with certain solid tumors that have not improved with standard treatments or for whom no standard treatment exists. The study is divided into parts: first, to find safe and effective doses, then to test those doses in m…

This phase 2 trial is testing a novel combination for people with metastatic pancreatic cancer that has progressed after standard first-line chemotherapy. The approach combines a device that alternately freezes and heats the tumor (multimodal thermal therapy) with a personalized …

This early-stage trial is testing an experimental treatment called the IKS04 regimen in people with advanced cancers of the digestive system, including colorectal, stomach, pancreatic, and bile duct cancers. The regimen combines a targeted antibody-drug conjugate with an addition…

This study tests an experimental drug called SKB565 in 180 adults with advanced solid tumors that have not responded to or cannot tolerate standard treatments. The trial has three stages to find the safest dose, check how the drug moves through the body, and see if it shrinks tum…

This trial is testing whether a new oral drug called HRS-2329, which blocks multiple RAS proteins, can shrink tumors or slow disease when combined with other anti-cancer therapies. It is enrolling adults with advanced pancreatic cancer that has RAS mutations or amplifications and…

This phase II trial is testing whether adding an immunotherapy drug (serplulimab) and a targeted antibody (bevacizumab) to standard chemotherapy can help people with metastatic pancreatic cancer that has progressed after initial treatment. The study enrolls about 34 adults whose …

This early-stage trial tests a new drug called SHR-4685 in people with advanced solid tumors that have not responded to other treatments. The main goals are to check the drug's safety, find the best dose, and see how the body processes it. About 170 adults aged 18 to 75 with meas…

This trial is testing an experimental drug called ML-016, a nanoparticle form of the chemotherapy doxorubicin, in people with advanced solid tumors that have spread to the lungs or liver. The study aims to find the safest dose and see whether the drug can shrink tumors or slow th…

This early-phase trial tests an experimental drug called ISM5939, taken as a pill, in people with advanced or metastatic solid tumors that have not responded to standard treatments. The study will first test the drug alone, then in combination with chemotherapy (cisplatin or doce…

This trial tests an experimental drug called HMPL-A830 in adults with advanced solid tumors that have not responded to standard treatments. The study has two parts: first, finding a safe dose, then testing that dose in more people to see if it can shrink tumors. The goal is to un…

This early-stage trial is testing an experimental oral drug called HW221043 in adults with advanced solid tumors who have no standard treatment options left. The study has two parts: first, finding a safe dose, then expanding to see if the drug can shrink tumors or slow their gro…

This early-phase trial tests an experimental drug called XNW28012 in people with metastatic pancreatic cancer whose disease has worsened after at least one prior treatment. XNW28012 is an antibody-drug conjugate designed to seek out a protein called tissue factor on cancer cells …

This trial tests a care package called the 'WARNING Pack' for people aged 75 and older with cancer. The pack helps doctors spot early signs of age-related problems and provides a guide for managing them. The goal is to prevent a decline in quality of life and reduce the risk of g…

This phase 1 trial tests an experimental drug called TJ037130 in adults with advanced solid tumors, including ovarian, gastric, and endometrial cancers that have spread. The main goal is to check the drug's safety and find the best dose for future studies. Participants receive TJ…

This study tests an experimental oral drug called elraglusib in adults with advanced solid tumors that have spread or are not responding to standard treatments. The trial aims to find the safest dose and evaluate how the body processes the drug, while also looking for early signs…

This trial investigates whether raising the body's core temperature to 41.5°C for 4 hours, called whole-body hyperthermia, can improve outcomes when added to standard chemotherapy for people with metastatic pancreatic cancer that has progressed after initial treatment. The study …

This early-stage trial tests a new drug called SI-B036, a bispecific antibody designed to fight advanced gastrointestinal and other solid tumors. The study involves about 16 adults with tumors that have spread or cannot be removed. Researchers aim to find a safe dose and see if t…

This clinical trial tests whether adding focused ultrasound (IMD10) to standard chemotherapy can help people with borderline resectable or locally advanced pancreatic cancer. The study will enroll 136 adults aged 18-85 with confirmed pancreatic ductal adenocarcinoma. Half will ge…

This early-stage trial tests an experimental therapy called GKL-006Allo, made from donor immune cells (iNKT cells), in people with advanced solid tumors that have not responded to standard treatments. The main goals are to check the therapy's safety and how the body processes it.…

This study tests whether adding ivermectin, a drug used for parasitic infections, can improve the immune response in people with solid tumors who are already receiving immunotherapy. About 80 adults will take either a moderate or high dose of ivermectin for four weeks alongside t…

This study tests an experimental drug called HSK41959, taken as a tablet, in combination with standard cancer treatments for people with advanced solid tumors that lack a gene called MTAP. The trial includes patients with non-small cell lung cancer, pancreatic cancer, and other a…

This trial tests a new drug called VBC108 in people with advanced solid tumors that have not responded to standard treatments. VBC108 is designed to attach to two specific proteins (CLDN18.2 and CDH17) found on some cancer cells and deliver a toxic payload to kill them. The study…

This study tests a new biologic drug called XYA02 in 190 adults with advanced solid tumors (including lung, ovarian, and pancreatic cancers) that have not responded to standard treatments. The main goals are to check safety, find the best dose, and see if the drug can shrink tumo…

This study tests a new approach called photoimmunotherapy for people with locally advanced or borderline resectable pancreatic cancer. Patients receive an injection of ASP-1929, a drug that attaches to cancer cells and becomes active when exposed to a specific light. During surge…

This study tests an experimental drug called LM-364, given alone or with another cancer drug (tislelizumab), in people with advanced solid tumors that have not responded to standard treatments. The goal is to find a safe dose and see if the drug can shrink tumors. About 90 adults…

This study tests an experimental oral drug called GFH276 combined with either cetuximab or standard chemotherapy in people with advanced solid tumors or pancreatic ductal adenocarcinoma (PDAC) that have a RAS mutation. The goal is to see if the combination is safe, tolerable, and…

This early-phase study tests a new drug called KIVU-305 in people with advanced solid tumors that have stopped responding to standard treatments. The drug is designed to target and attack cancer cells while sparing healthy ones. The main goal is to find a safe dose and see if the…

This trial tests an experimental drug called HSK46256, which blocks a protein called PARP1 that helps repair DNA in cancer cells. The study includes adults with advanced solid tumors who have not responded to standard treatments. Researchers aim to find the safest dose and check …

This phase 2 trial tests the drug inavolisib in people with pancreatic ductal adenocarcinoma whose cancer has worsened after prior chemotherapy. The study aims to see if inavolisib can shrink tumors or slow disease progression. Participants take inavolisib daily by mouth, and the…

This trial tests an experimental drug called VBC106 in people with advanced solid tumors that have not responded to standard treatments. VBC106 is designed to target two proteins (FRα and MSLN) found on some cancer cells, delivering a toxic payload directly to the tumor. The stud…

This phase 2 trial tests whether adding the experimental drug HRS-4642 to standard chemotherapy, with or without the immunotherapy adebrelimab, can shrink pancreatic tumors before surgery. The study enrolls adults aged 18-70 with pancreatic ductal adenocarcinoma who have at least…

This trial tests a new drug called DN022150 in people with advanced pancreatic cancer that has a specific genetic change called KRAS G12D. Participants have already received at least one prior treatment. The study compares DN022150 alone against standard chemotherapy options to s…

This pilot study tests a new device that uses radiofrequency energy to seal the pancreas during robotic surgery to remove the tail of the pancreas. The device, called Attachable Coolingbis®, is designed to reduce the common complication of pancreatic fluid leaks. Twenty adults wi…

This phase 2 trial tests a new treatment approach for people with locally advanced pancreatic cancer that cannot be removed by surgery. Participants receive targeted radiation therapy followed by a combination of two immunotherapy drugs (ipilimumab N01 and sintilimab) plus standa…

This study tests a new drug called becotatugvedotin combined with the chemotherapy gemcitabine for people with advanced pancreatic cancer that has not responded to first-line treatment. The trial has two phases: first, to find the safest dose of the new drug, and second, to see h…

This study tests a new treatment called VG2025, a modified herpes simplex virus designed to infect and kill cancer cells while also boosting the immune system. The trial enrolls adults with advanced solid tumors that have not responded to standard therapies and who have previousl…

This early-phase trial will test whether adding semaglutide (a GLP-1 drug used for diabetes and weight loss) to standard chemotherapy is safe and tolerable for people with metastatic pancreatic, colorectal, or liver cancer. About 30 participants will receive weekly semaglutide in…

This trial provides continued access to three experimental Bicycle therapies—zelenectide pevedotin, nuzefatide pevedotin, and BT7480—for people with advanced solid tumors who are already benefiting from them in another study. Participants continue their same treatment while resea…

This study tests a surgery called total pancreatectomy with islet autotransplantation (TPIAT) in 30 adults with certain pancreatic tumors who are at high risk for a dangerous leak after standard surgery. The procedure removes the entire pancreas and transplants the insulin-making…

This extension trial follows patients with advanced solid tumors who are already receiving or have received gotistobart in earlier studies. The goal is to assess long-term safety and overall survival over an extended period. Participants must be 18 or older and have been part of …

This Phase 1 trial tests D3L-002, a new drug that targets two immune checkpoints (TIGIT and PVRIG) to help the immune system fight cancer. It is for 24 adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety, find the r…

This study tests a new drug called samuraciclib added to standard chemotherapy for people with a specific type of advanced pancreatic cancer (basal-like). The goal is to find the safest dose and see if the combination helps shrink tumors or slow the cancer. About 67 adults with n…

This early-stage trial is testing a new cell therapy called GK01 in 10 people with advanced solid tumors that have stopped responding to standard treatments. The therapy uses the patient's own immune cells (T cells) that are trained to attack the tumor. The main goal is to check …

This early-stage trial tests LNF2105, a drug designed to target and deliver a toxin to cancer cells that have a protein called Nectin-4 on their surface. It will enroll about 294 adults with advanced solid tumors (such as bladder, breast, or lung cancer) who have run out of stand…

This early-stage trial tests a new approach to CAR-T therapy where a virus is injected directly into the bloodstream to reprogram a patient's own immune cells to attack cancer. It involves 91 adults with advanced solid tumors who have run out of standard options. The main goal is…

This study tests a new drug called DN022150 combined with standard chemotherapy (AG) as a first treatment for advanced pancreatic cancer that has a specific genetic change called KRAS G12D. About 465 adults aged 18-75 who have not had prior treatment for advanced disease will tak…

This early-stage trial is testing two experimental drugs, OVV-01 and AK112, in 30 people with advanced solid tumors that have not responded to standard treatments. OVV-01 is given both into a vein and directly into the tumor, while AK112 is given into a vein. The main goals are t…

This early-phase trial tests an experimental drug called CLSP-5282 in up to 140 adults with advanced solid tumors (like lung, pancreatic, or colorectal cancer) that have a specific genetic change called KRas G12V. The drug is given by IV infusion. The main goals are to check safe…

This early-phase trial is testing whether injecting the MMR vaccine directly into pancreatic tumors is safe and can help shrink them. The study will include 20 adults with borderline resectable or unresectable pancreatic cancer who have already completed standard chemotherapy and…

This early-stage trial tests whether combining two drugs—selumetinib and DS-8201a—can safely shrink or control advanced pancreatic cancer that has a specific genetic change (KRAS mutation) and a protein called HER2. About 31 adults with cancer that cannot be removed by surgery or…

This early-phase trial tests a new peptide nanovaccine (ONVAX-01) together with an anti-PD-1 antibody and standard chemotherapy in 9 people with advanced pancreatic cancer that has worsened after prior treatment. The main goals are to see if the combination is safe and whether it…

This Phase 1 trial tests MST-168, an antibody-drug conjugate designed to target and kill cancer cells. It will enroll 420 adults with advanced solid tumors that have specific markers. The main goals are to check safety, find the right dose, and see early signs of tumor shrinkage.

This phase II trial tests whether a genetic signature can personalize chemotherapy for people with borderline resectable pancreatic cancer. About 110 participants will receive either a standard chemo regimen or one chosen based on their tumor's genetic profile. The goal is to see…

This study tests a new drug called JAB-23E73, which targets KRAS gene changes, combined with two standard chemotherapies (nab-paclitaxel and gemcitabine) in people whose pancreatic cancer has spread and who haven't had prior treatment. The goal is to see if the combination is saf…

This early-phase trial tests a new drug called YKYY031 in 76 people with advanced solid tumors (like colorectal or pancreatic cancer) that have stopped responding to standard treatments. The main goals are to check safety, find the right dose, and get a first look at whether the …

This study tests a new drug (GV20-0251) combined with an immunotherapy (anti-PD-1) in people with advanced solid tumors that have not responded to or cannot tolerate standard treatments. About 227 adults with various cancers, including lung, breast, and colorectal, will participa…

This study tests a drug called Trastuzumab Rezetecan in 15 adults with advanced solid tumors that have the HER2 protein. The goal is to see if the drug can shrink tumors. Participants get the drug by IV every 3 weeks. This is for people whose cancer has worsened after other treat…

This early-phase trial tests a new drug called AB801, which blocks a protein (AXL) that helps cancers grow and resist treatment. It is given alongside chemotherapy and immunotherapy to people with bile duct or pancreatic cancer that is either borderline resectable, locally advanc…

This early-stage trial tests a new drug called ONC-783 in 20 people with advanced solid tumors, including colorectal, ovarian, pancreatic, or breast cancer. The drug is a bispecific antibody designed to help the immune system attack cancer cells. The main goal is to find a safe d…

This study tests a new drug called FG-B901, a bispecific antibody that targets two immune proteins (PD-L1 and CD40) to activate the immune system against tumors while reducing side effects. It is given alone or with chemotherapy to 264 adults with advanced solid tumors that have …

This early-stage study tests a new tablet, LT-010391, in people with advanced solid tumors (lung, colon, or pancreatic cancer) that have a specific genetic change called KRAS G12D. The main goals are to check safety and find the right dose. About 198 participants who have tried o…

This early study tests if a new, needle-based treatment using brief electric pulses can safely destroy certain pancreatic tumors without surgery. The treatment aims to spare healthy tissue nearby. About 12 adults with specific pancreatic cysts or low-grade tumors will be enrolled…

This study tests a new drug (SYS6006) combined with another drug (Enlonstobart) in people with advanced solid tumors that cannot be removed by surgery or have spread. The goal is to see if the combination is safe and works better than Enlonstobart alone. About 264 adults will tak…

This early-stage study tests a new drug called QLC5508 in 48 adults with advanced solid tumors that have stopped responding to treatment. The main goals are to check if the drug affects heart rhythm, compare two versions of the drug, and see how it interacts with other medicines.…

This early-phase study tests a new treatment called CAR-DC for people with advanced solid tumors (like lung, liver, or stomach cancer) that have not responded to standard care. The therapy uses a patient's own immune cells, modified in a lab to recognize and attack cancer cells. …

This early-stage trial tests a new drug called Hemay5087 in 24 people with advanced solid tumors that have not responded to standard treatments or have no standard options. The main goals are to check safety, find the right dose, and get a first look at whether the drug can shrin…

This early-stage study tests a new drug called HH160 in about 56 adults with advanced solid tumors (cancers that have spread). The main goals are to check safety, find the best dose, and see if the drug shrinks tumors. Participants will receive HH160 alone or with other cancer tr…

This early-phase trial tests a new drug called WSK-IM02 in 9 people with advanced solid tumors that have spread to cause fluid buildup around the lungs or in the belly. The drug is given directly into the chest or abdomen to see if it is safe and can shrink tumors or reduce fluid…

This early-phase trial tests a combination of two drugs, CVL006 and 9MW2821, in 108 adults with advanced solid tumors that have not responded to standard therapy. The goal is to find a safe dose and see if the combination can shrink tumors. The study is not yet recruiting.

This early-stage trial tests a new drug called CS231295 in 42 adults with advanced solid tumors that have stopped responding to standard treatments. The drug works by blocking certain proteins that help tumors grow and form blood vessels. The main goals are to check safety, find …

This early-stage trial tests a new drug called HF50 in 45 adults with advanced solid tumors that have not responded to standard treatments. HF50 is designed to target HER2 on cancer cells and boost the immune system. The main goals are to check safety, find the right dose, and se…

This study tests a new drug combination for people with metastatic solid tumors that lack a gene called MTAP. The drugs, BMS-986504 and pemetrexed, aim to stop cancer cells from growing. The trial will check safety and how well the combo works in 72 participants.

This early-phase study tests a new drug called IN10028 in 75 adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety, find the best dose, and see if the drug shrinks tumors when used alone or with other cancer drugs. Th…

This early-stage trial tests a new drug (non-cationic peptide-CD47 siRNA) in about 9 people with advanced solid tumors that have not responded to other treatments. The drug works by blocking a 'don't eat me' signal on cancer cells, helping the immune system recognize and attack t…

This early-stage trial tests a new drug called JH021 in 60 people with advanced solid tumors that have stopped responding to standard treatments. JH021 is a special antibody that targets two cancer-related proteins, EGFR and cMET, to potentially slow or stop tumor growth. The mai…

This early-stage trial tests a personalized cancer vaccine called ODI-2001 in 77 people with advanced colon or pancreatic cancer that has spread or cannot be removed. The vaccine is custom-made for each patient's tumor and is given along with a drug that boosts the immune system.…

This study tests a new treatment for people with advanced pancreatic cancer that has not been treated before. It combines a hedgehog inhibitor (NLM-001) with standard chemotherapy and two immunotherapy drugs. The goal is to see if this combination shrinks tumors better than chemo…

This study tests a new drug called SKB118 in 332 adults with advanced solid tumors that have not responded to standard treatments. The drug is given by IV every three weeks. The trial will first find the safest dose, then check if it can shrink tumors. It is currently not recruit…

This early-phase study tests a new drug, CS08399, in people with advanced solid tumors or lymphoma that have a specific gene deletion (MTAP). The main goal is to find a safe dose and understand how the drug works in the body. About 186 participants will take part, and researchers…

This phase 3 trial tests whether the experimental drug MRG004A, combined with best supportive care, helps people with advanced pancreatic cancer live longer compared to a placebo. The study plans to enroll 231 adults whose cancer has not responded to standard treatments. Particip…

This early-stage trial tests a new therapy called MT-601, which uses a patient's own immune T-cells trained to recognize multiple cancer-related targets. It is for people with advanced pancreatic cancer that cannot be removed by surgery or has spread. The study will check safety …

This trial looks at whether children with cancer who develop a fever and low white blood cells can safely stop antibiotics earlier than usual. About 136 children will be randomly assigned to either stop antibiotics within 24 hours or continue standard treatment. The goal is to se…

This early-phase trial tests a new drug called SYS6051 in 114 adults with advanced solid tumors that have not responded to standard treatments. The study aims to find a safe dose and check for early signs of tumor shrinkage. Participants receive the drug by IV every three weeks.

This study tests a drug called lorigerlimab in people with advanced pancreatic cancer that has a specific genetic makeup (BRCA, PALB2, or RAD51C/D mutations). The goal is to see if the drug can shrink tumors. About 40 adults will take part, and the study is not yet recruiting.

This early-stage study tests a new drug called NPX372 in people with advanced solid tumors that have not responded to standard treatments. The drug is designed to help the body's immune cells recognize and attack cancer cells. The main goals are to check the drug's safety and fin…

This early-phase study tests a new drug combination (L19IL2 plus ruxolitinib) in people with advanced kidney, pancreatic, or colorectal cancers that have stopped responding to standard treatments. The main goals are to find a safe dose and check for side effects. About 96 partici…

This study looks at envafolimab, a cancer drug given as a quick shot under the skin instead of a long IV drip. It is for adults with advanced solid tumors who have not responded to standard treatments. The goal is to see how well it controls tumors and what side effects occur in …

This phase II trial tests a drug called sacituzumab tirumotecan in 30 people with advanced pancreatic cancer that has worsened after at least one prior treatment. The drug is given by IV every two weeks. The main goal is to see if it can shrink tumors, and researchers will also t…

This early-phase trial tests an experimental drug called FXB0871 in about 138 adults with advanced solid tumors, including non-small cell lung cancer and liver cancer, that have stopped responding to standard treatments. The study has two parts: first, finding a safe dose, and se…

This early-stage trial tests a new type of cell therapy for people with advanced pancreatic cancer that has stopped responding to chemotherapy. The treatment uses a patient's own immune cells, called macrophages, that are engineered in a lab to recognize and attack cancer cells c…

This early-phase trial tests whether adding the experimental drug NRT6008 to standard chemotherapy is safe and helps shrink tumors in people with advanced pancreatic cancer that cannot be removed by surgery. About 10 adults aged 18 to 85 with this condition will receive the combi…

This early-stage trial tests whether adding three new drugs (nogapendekin alfa inbakicept, sotevtamab, and zabadinostat) to standard chemotherapy can safely shrink pancreatic tumors that are hard to remove. About 30 adults with borderline resectable or locally advanced pancreatic…

This study tests whether changing the order of steps during a Whipple surgery for pancreatic head cancer can help surgeons remove the tumor more completely and lower the chance of cancer coming back. About 150 adults with operable pancreatic cancer will be randomly assigned to ei…

This phase 2 trial tests an experimental oral liquid called BLEX 404 combined with standard chemotherapy (gemcitabine) in 40 people with advanced pancreatic cancer that cannot be removed by surgery or has spread. The study first finds a safe dose, then checks if the combo shrinks…

This study tests a device called ONCObind that filters cancer cells from the blood of people with advanced pancreatic or colorectal cancer that has not responded to standard treatments. About 120 adults will receive the filtering procedure multiple times to see if it is safe and …

This early-stage trial tests crotoxin, a protein from rattlesnake venom, given intravenously to 24 adults with advanced solid tumors that have not responded to standard therapy. The main goal is to see if a slow dose increase can make the drug safer and better tolerated. Research…

This study tests a new drug called ALK-N001 in 190 adults with advanced solid tumors that have not responded to standard treatments. The drug is given by IV every 2 or 3 weeks. Researchers will check if it shrinks tumors, how safe it is, and how the body processes it. The goal is…

This study tests a new drug called KHN922 in people with advanced solid tumors that have not responded to standard treatments. KHN922 is an antibody-drug conjugate designed to target HER3 proteins on cancer cells and deliver two anti-cancer drugs directly to them. The trial will …

This early-phase trial is testing a new chemotherapy drug called RP-001 in 66 adults with advanced solid tumors, including colorectal and pancreatic cancers. The main goals are to check safety, find the best dose, and see if the drug can shrink tumors. It is an open-label study, …

This early-stage trial tests a new biologic drug, SIG001, in 66 people with advanced solid tumors. The main goals are to check safety, find the right dose, and see how the drug behaves in the body. Participants receive SIG001 intravenously every two weeks and are monitored for si…

This early-phase trial tests whether delivering the chemotherapy drug gemcitabine directly into the artery feeding the tumor can improve surgical outcomes for people with borderline resectable pancreatic cancer. Ten participants will receive standard chemo and radiation, followed…

This early-phase trial tests whether adding the migraine drug rimegepant to standard chemotherapy can help people with metastatic pancreatic cancer. About 30 adults who have not had prior treatment will receive the combination. Researchers will track how long the cancer stays und…

This study tests an experimental oral drug, BPI-572270, in 120 adults with advanced solid tumors (lung, colorectal, or pancreatic cancer) that have specific RAS gene mutations. The trial has two phases: first to find a safe dose and check for side effects, then to see if the drug…

This early-phase study tests a new drug called QLS5308 in about 192 adults with advanced solid tumors that have spread and cannot be removed by surgery or radiation. The main goals are to check the drug's safety, find the best dose, and see if it can shrink tumors. Participants m…

This study tests an experimental drug called QLS5132, given with other cancer treatments, for people with advanced solid tumors like stomach, lung, endometrial, and ovarian cancers. The goal is to find safe doses and see if the combination shrinks tumors. About 626 participants w…

This study tests whether adding a heat-based treatment called radiofrequency ablation (RFA) to a standard procedure (ERCP) can help people with advanced pancreatic cancer that has spread to the liver live longer. About 178 adults with limited liver spread will be randomly assigne…

This Phase III trial is testing whether adding the experimental drug chiauranib and an immunotherapy (toripalimab) to standard chemotherapy can help people with metastatic pancreatic cancer live longer. About 558 participants will be randomly assigned to receive either the full c…

This Phase 2 trial tests a combination of tunlametinib and anti-EGFR antibodies (cetuximab β or nimotuzumab) in 90 adults with advanced colorectal or pancreatic cancers that have RAS mutations and have not responded to standard treatments. The goal is to see if the combo shrinks …

This study tests whether injecting chemotherapy directly into a pancreatic tumor using an endoscope (EUS-guided) plus standard chemo works better than standard chemo alone. About 20 adults with locally advanced pancreatic cancer will take part. The goal is to see if the combinati…

This early-stage study tests a new drug called T320 in 150 people with advanced solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety, find the best dose, and see if it can shrink tumors. Participants receive T320 every two wee…

This early-stage study tests a new treatment for people with advanced ovarian cancer or other solid tumors that have come back or not responded to standard therapy. The treatment uses a patient's own immune cells that are genetically modified to better recognize and attack cancer…

This study tests a new drug called IBI343 combined with chemotherapy for people with a specific type of pancreatic cancer that is on the edge of being removable by surgery. The goal is to shrink the tumor enough so it can be surgically removed, then follow up with more chemo. Abo…

This early-phase trial tests a new type of cell therapy called CAR-Macrophages in 20 adults with advanced solid tumors. The immune cells are modified to target specific markers on cancer cells (HER2, PSMA, FAP) and are given by IV. The main goals are to check safety, find the bes…

This early study tests a new treatment called CAT-101, which uses a patient's own immune cells (dendritic cells) loaded with a cancer protein (mKRAS) to help the body fight tumors. It is for people with advanced pancreatic cancer or other solid tumors that have a specific KRAS mu…

This early-stage trial tests an experimental treatment called CBG131 for adults with advanced stomach or pancreatic cancer that has a specific marker (CLDN18.2). The therapy uses a patient's own immune cells, modified in a lab to target and attack cancer cells. The main goals are…

This early-phase trial will test whether adding the study drug NP137 to standard chemotherapy (FOLFIRINOX) can change the behavior of pancreatic cancer cells before and after surgery. About 25 people with resectable pancreatic cancer will receive the combination, and researchers …

This early-stage study tests if combining radiation therapy with an experimental immunotherapy called PCX12 is safe for people with locally advanced pancreatic cancer. About 24 participants who have already had chemotherapy will receive radiation followed by injections of PCX12 d…

This Phase 3 trial tests whether adding the experimental antibody FG-M108 to standard chemotherapy (gemcitabine and nab-paclitaxel) helps people with advanced pancreatic cancer live longer. About 524 participants with Claudin18.2-positive tumors will be randomly assigned to recei…

This early-phase study tests a new drug called QLS5316 in about 300 adults with advanced solid tumors (such as colorectal, stomach, head and neck, or lung cancer) that have not responded to standard treatments. The main goals are to check the drug's safety, find the right dose, a…

This early-phase study tests whether a new cell therapy called B7-H3 CAR T cells is safe and can help children and young adults whose solid tumors have returned or stopped responding to standard treatments. About 40 participants will receive their own immune cells that have been …

This early-stage trial tests a procedure called microtransplantation (MST) combined with chemotherapy in 10 adults with advanced or relapsed solid tumors. The goal is to see if MST can help control the disease and improve recovery of blood cells after chemo. The study focuses on …

This study tests whether a remote temperature monitor can help detect fever early in children undergoing chemotherapy who are at risk of a serious infection called febrile neutropenia. About 30 children from families with social or emotional challenges will either use a wearable …

This early-phase trial tests a new therapy called TCR-T cells, which are immune cells engineered to recognize and attack cancer cells with specific KRAS mutations (G12V or G12D). The study will enroll 25 adults with advanced solid tumors (like colorectal or lung cancer) who have …

This early-stage trial tests whether adding ATRA, SDK002, and an immunotherapy drug to standard chemotherapy is safe for people with advanced pancreatic cancer that cannot be removed by surgery. Ten participants will receive all five drugs together. The study will also track how …

This early-stage trial tests a new drug called FXS887 in 14 people with advanced solid tumors that have stopped responding to standard treatments. The drug works by blocking a protein (ATR) that cancer cells need to repair their DNA. The main goals are to check safety, find the r…

This Phase III trial tests whether adding targeted radiation and an immunotherapy drug (serplulimab) to standard chemotherapy can help people with advanced pancreatic cancer live longer. About 198 participants who have not had prior treatment will be randomly assigned to receive …

This study tests a new drug, HX111, in about 70 people with advanced solid tumors or lymphoma that has not responded to other treatments. The goal is to find a safe dose and see if the drug can shrink tumors. It is an early-stage trial, so the main focus is on safety and side eff…

This Phase 2 trial tests whether combining two platelet-boosting drugs (hetrombopag and rhTPO) works better than hetrombopag alone for cancer patients with dangerously low platelets from treatment. About 204 adults with solid tumors will be randomly assigned to one of the two gro…

This study tests a new first-line treatment for people with pancreatic cancer that has spread to the liver. The treatment combines chemotherapy delivered directly to the liver with two immunotherapy drugs. The goal is to see if this approach can slow or stop cancer growth. The st…

This study tests an experimental oral drug called XNW34017 in 150 people with advanced solid tumors who have not responded to or cannot tolerate standard treatments. The trial has two parts: first, finding a safe dose, then expanding to see if the drug can shrink tumors. It is an…

This early-phase study tests a new approach for people with pancreatic cancer that has spread to the liver and who have already tried standard chemotherapy. The treatment combines standard chemotherapy drugs with a special ultrasound technique that uses tiny bubbles to help deliv…

This study tests a drug called ivarmacitinib in 72 people with advanced solid tumors who had to stop their cancer immunotherapy because of severe immune-related side effects. The goal is to see if the drug can control those side effects and, if successful, allow patients to safel…

This study tests several new anti-cancer drugs and technologies in 600 people with rare solid tumors that have spread or cannot be removed. Participants will receive treatments matched to their tumor's unique genetic profile. The goal is to see if these therapies are safe and shr…

This study tests a new drug called HLX43 in 100 adults with advanced pancreatic cancer that has not responded to other treatments. The drug is designed to target and attack cancer cells while limiting harm to healthy cells. The goal is to see if it can shrink tumors or slow the d…

This study tests a combination of four drugs—tunlametinib, two chemotherapies, and a targeted antibody—as a first treatment for people with advanced pancreatic cancer that cannot be removed by surgery. The trial will enroll 28 patients who have not had prior therapy. Researchers …

This study tests a new drug called TYK-01054 for people with advanced solid tumors that have not responded to standard treatments. The drug is taken as a capsule and works by blocking a protein (TEAD) involved in cancer growth. The trial will check safety, find the best dose, and…

This study looks at whether actively treating diabetes with drugs like metformin or insulin can help people with metastatic pancreatic cancer live longer when they also receive standard chemotherapy. About 210 adults with both pancreatic cancer and diabetes will be enrolled. The …

This early-stage study tests a new treatment called KXV01 TCR Lentinvivo in 30 adults with advanced solid tumors that have not responded to standard therapies. The main goal is to check safety and find the right dose. The treatment uses a virus to deliver cancer-fighting genes in…

This phase 2 trial tests whether adding nimotuzumab, a targeted antibody, to standard chemotherapy can help people with high-risk pancreatic cancer that can still be surgically removed. About 156 participants will receive either the drug combo or a placebo before and after surger…

This phase 2 trial tests a combination of PRaG-1 Cordycepin Tablets (from a fungus), radiation therapy, immune-boosting injections, and immunotherapy drugs in 65 adults with advanced solid tumors who have no standard treatment options. The goal is to see if this mix improves immu…

This early-stage trial tests an experimental drug called ACC-1898, taken as a daily pill, in adults with advanced solid tumors (like liver, kidney, or stomach cancer) that have not responded to standard treatments. The main goals are to find a safe dose and see how the body handl…

This early-phase trial tests a new drug called TB511 in people with advanced solid tumors (lung, prostate, colorectal, or liver cancer) that have stopped responding to standard care. The study has two parts: first, finding the safest dose of TB511 alone; second, testing TB511 com…

This study tests a new mRNA vaccine designed to help the immune system attack cancer cells. The vaccine targets a protein found only in tumors and is given together with an immunotherapy drug (anti-PD-1). About 60 adults with advanced solid tumors that cannot be removed by surger…

This study looks at whether giving a higher dose of radiation (60-65 Gy) using a precise technique called VMAT can help people with inoperable pancreatic cancer live longer and keep their tumors under control compared to the standard lower dose (45-50.4 Gy). Researchers will foll…

This phase 2 trial is testing whether adding the immunotherapy drug adebrelimab to standard chemotherapy can help shrink pancreatic tumors before surgery. About 30 people with resectable pancreatic cancer will receive the combination, and researchers will measure how many tumors …

This early-phase trial tests two drugs (cosibelimab and balixafortide) together in people with advanced pancreatic cancer that has stopped responding to standard chemotherapy. The main goal is to find the safest dose and check for side effects. About 24 adults will take part in t…

This early-phase trial will test a new tumor vaccine (SapDM275) combined with standard chemotherapy in 13 people with metastatic pancreatic cancer who have not had prior treatment. The vaccine aims to help the immune system attack cancer cells. The main goal is to check safety, b…

This Phase 2 trial will test an experimental drug called SSGJ-706 combined with standard chemotherapy (and sometimes another drug, bevacizumab) in 300 people with advanced gastrointestinal cancers that cannot be surgically removed. The goal is to see if the combination is safe an…

This study tests special radioactive drugs that can both find and treat solid tumors that have spread to the brain. Ten adults with advanced breast cancer and active brain metastases will receive a single dose of a diagnostic agent to see if it lights up the brain tumors on a sca…

This early-stage trial tests a new treatment for adults with solid tumors that have come back or not responded to standard therapy. The treatment uses a patient's own immune cells, modified in a lab to better recognize and attack cancer cells that carry a protein called GPC3. The…

This study tests whether a specific sequence of two different chemotherapy combinations, each paired with an immunotherapy drug (PD-L1 antibody), can shrink borderline resectable or locally advanced pancreatic cancer enough to allow surgical removal. About 77 adults with this typ…

This early-phase study tests a new treatment called KXV01 TCR Lentinvivo for people with advanced solid tumors that have not responded to standard therapies. The main goals are to check safety and find the right dose. About 30 adults aged 18 to 70 will take part, and researchers …

This early-stage study tests a new drug, ATB-320, in 24 adults with solid tumors that have spread or are getting worse despite standard treatments. The main goal is to find a safe dose and check for side effects. Participants must provide tumor samples and have tumors that can be…

This study tests an experimental oral drug called GFH276 in people with advanced solid tumors that have RAS mutations, including pancreatic, lung, and colorectal cancers. The trial has two parts: Phase 1 finds the safest dose, and Phase 2 checks if the drug shrinks tumors. About …

This early-phase trial tests a personalized gene therapy called KXV01 TCR Lentinvivo Injection for people with advanced solid tumors that have not responded to standard treatments. The therapy uses a virus to deliver cancer-fighting genes into the patient's own immune cells. The …

This study tests a drug called Romiplostim N01 in 106 cancer patients whose platelets drop due to chemo, radiation, or immunotherapy. The goal is to see if it can safely raise platelet counts better than the current standard treatment. Patients will be randomly assigned to receiv…

This early-phase trial will test a combination of two drugs—JDB153 (taken as a pill) and serplulimab (given by IV)—in 10 people with advanced pancreatic cancer that has not responded to standard treatments. The main goals are to check safety and see if the drugs can shrink tumors…

This early-phase trial is testing a combination of two experimental drugs, IMM2510 and IMM01, in about 104 people with advanced solid tumors that have already been treated. The goal is to find safe doses and see if the combination can shrink tumors. The study is not yet recruitin…

This study tests a new drug called CVL006 combined with standard chemotherapy or other targeted drugs in people with advanced solid tumors that have not responded to previous treatments. The trial has two phases: first, to find the safest dose, and second, to see if the combinati…

This phase 2 trial tests whether romiplostim N01 can safely raise low platelet counts in 60 adults with solid tumors who have had radiotherapy combined with other treatments. The main goal is to see if platelet counts increase by at least 50 billion per liter within two weeks. Th…

This phase 3 trial will test whether giving chemotherapy before surgery helps people with resectable left-sided pancreatic cancer live longer compared to surgery alone. About 381 participants will be randomly assigned to either neoadjuvant chemotherapy (FOLFIRINOX or gemcitabine/…

This early-phase trial tests a new treatment called CD318-CAR-T cells for people with advanced pancreatic cancer that has worsened after standard therapy. The therapy uses a patient's own immune cells, which are modified in a lab to recognize and attack cancer cells. The study ai…

This trial tests whether a new imaging agent called INR 202, used with a PET/CT scan, can detect more tumors than the standard FDG-PET/CT in people with advanced solid tumors. Thirty adults with advanced cancer will receive both scans to compare how many lesions each method finds…

This pilot study tests whether a structured case-finding pathway can help detect pancreatic cancer earlier in Swiss primary care. Adults aged 60 or older with warning signs like new-onset diabetes, unexplained weight loss, or a family history of pancreatic cancer are invited to u…

This study is testing a simple breath test to help detect gastrointestinal cancers—including cancers of the esophagus, stomach, pancreas, liver, and bowel—at an earlier stage. The test measures tiny molecules in exhaled breath that may be linked to these cancers. Participants pro…

This study aims to find molecular clues that could predict whether certain pancreatic growths will turn into cancer. Researchers will analyze tissue from patients having pancreatic surgery, using advanced genetic and protein tests on both the original tissue and lab-grown 3D cell…

This study tests whether a combined PET/MRI scan can detect and measure liver scarring (fibrosis) in people with primary sclerosing cholangitis (PSC). Ten participants will receive two experimental tracers that bind to scar tissue, and results will be compared to standard tests l…

This study investigates whether a new ultrasound technology called Superb Microvascular Imaging (SMI) can accurately analyze material inside pancreatic cysts (PIMPTs) without using a contrast agent. Currently, doctors inject a contrast dye during endoscopic ultrasound to assess c…

This study tests a new radioactive tracer called 68Ga-FAPI-PSMA for PET/CT scans to see if it can find and stage solid tumors (like prostate, liver, and ovarian cancers) better than current tracers. About 20 adults with suspected or confirmed tumors will receive the tracer and ha…

This early-phase trial tests a new radioactive tracer (64Cu-DOTA-A2DM) for PET scans in people with advanced pancreatic cancer that has spread. The tracer is designed to attach to a protein called PSCA found on some pancreatic cancer cells, making them visible on the scan. The st…

This study tests a new radioactive tracer called 68Ga-MY for PET scans. It targets a protein (5T4) found on many cancer cells but rarely on healthy cells. About 20 people with lung or breast cancer will get both a standard FDG scan and a 68Ga-MY scan. Researchers will compare the…

This study tests a new PET imaging agent, 68Ga-cPP-BCH, to detect PD-L1 protein levels in tumors of people with lung cancer, melanoma, or other solid tumors. The goal is to see if this scan can identify who might benefit from anti-PD-1/PD-L1 immunotherapy without needing a tissue…

This study tests two new ultrasound techniques to help doctors tell the difference between common pancreatic cancer and other types of pancreatic growths. About 150 adults with a solid pancreatic mass will get these advanced scans. The goal is to see if these methods can improve …

This phase 2 trial is testing an experimental drug called SIR2501 in adults with solid tumors who are about to receive paclitaxel-based chemotherapy. The goal is to see if SIR2501 is safe, tolerable, and might reduce the development of chemotherapy-induced peripheral neuropathy—a…

This study will test different methods to prevent infections and other problems from central lines (tubes placed in large veins) in 2,500 patients. It compares special antimicrobial caps and a skin anchor device against standard care. The goal is to find the best ways to keep pat…

This study tests whether the supplement glutamine can prevent nerve damage caused by the chemotherapy drug vincristine in children and teens with cancer. About 70 participants, aged 6 to 18, will take glutamine twice daily for 14 days during their treatment. Researchers will trac…

This early-phase trial tests whether a device that blocks signals from the vagus nerve can safely help patients with metastatic pancreatic cancer who are experiencing severe weight loss (cachexia). The device is placed on the skin over the nerve and is used alongside chemotherapy…

This pilot trial tests a program called FamilyStrong, designed to help family caregivers of people with advanced cancer manage their own distress. Caregivers receive monthly phone calls from a trained lay navigator who screens for stress, identifies their biggest concerns, and of…

This trial tests whether regular text-message check-ins can help advanced cancer patients get palliative care support earlier. Patients receive a text every two weeks asking them to rate their symptoms online. If any symptoms are concerning, a coordinator calls to assess and mana…

This pilot study tests whether delivering pain medication directly to the spinal cord via an implanted pump can better control severe pain in people with pancreatic cancer. The trial enrolls adults whose pain is not well managed by standard treatments or who cannot take typical p…

This study tests a program that pairs veterans with advanced cancer with a lay health worker who helps them discuss their goals and preferences for care with their doctors. The goal is to increase the number of veterans who have these important conversations and document their wi…

This trial tests whether a short course of precisely targeted radiotherapy can safely reduce severe pain in people with advanced pancreatic cancer. The radiation is aimed at the coeliac plexus, a network of nerves in the abdomen that often causes pain when affected by the tumor. …

This study tests if eating only within an 8-hour window each day (time-restricted eating) can reduce treatment side effects and improve quality of life for people with solid tumors starting adjuvant therapy after surgery. Fifty adults will be randomly assigned to follow this eati…

This study tests whether sucking on ice chips during chemotherapy can prevent or reduce the severity of painful mouth sores (oral mucositis) in cancer patients. 102 adults receiving 5-fluorouracil or methotrexate will be randomly assigned to either get ice chips during infusion p…

This study tests whether a 6-week dance-based exercise program can reduce nerve pain and improve quality of life in cancer patients who have nerve damage from chemotherapy. About 76 adults with solid tumors will either join the dance program or receive usual care. The goal is to …

This study looks at whether using a drug combination without opioids during anesthesia can lower the chance of confusion (delirium) after surgery in people 65 and older having gastrointestinal surgery. About 174 participants will be randomly assigned to receive either opioid-free…

This study tests whether a 15-minute hand and foot exercise routine can reduce nerve pain caused by Taxane chemotherapy in cancer patients. Fifty-eight adults with mild nerve symptoms will either do the exercises plus standard care or receive standard care alone. Researchers will…

This pilot study tests whether freeze-dried miracle fruit (MiraBurst) can improve taste changes in people with solid tumors undergoing cancer treatment. About 45 adults will take one mini-square before each meal for 90 days. The goal is to see if this simple supplement can ease a…

This study tests whether electroacupuncture (mild electrical pulses through thin needles) can help patients whose stomachs stop working properly after surgery for digestive tract tumors. Seventy-six adults who had such surgery and developed gastroparesis (stomach paralysis) will …

This study tests whether a 12-week supervised strength training program can help people with advanced pancreatic cancer maintain muscle mass and improve their quality of life. Ten participants who are receiving chemotherapy or immunotherapy will be randomly assigned to either the…

This study tests whether a personalized exercise program, tracked by a smartwatch, can help reduce fatigue in people who have finished chemotherapy for certain cancers (breast, colorectal, ovarian, pancreatic, or gastric). About 98 participants will be randomly assigned to either…

This study tests whether a traditional Chinese medicine hand-foot soak can reduce nerve pain and skin reactions caused by chemotherapy. About 300 adults with solid tumors who have these side effects will use the soak. The goal is to see if it improves symptoms and quality of life…

This early study tests whether selpercatinib, a drug already used for certain cancers, can help with cachexia (severe weight loss and appetite loss) in people with advanced lung, colon, or pancreatic cancer. Seven participants will take the drug twice daily for 12 weeks, with reg…

This study tests whether virtual palliative care (via video calls) works as well as standard in-person care for adults with cancer. About 252 participants will be randomly assigned to one of the two approaches. Researchers will measure quality of life, symptom burden, and satisfa…

This observational study looks at how pancreatic cancer changes immune cells in the blood. Researchers will compare blood samples from 50 people with newly diagnosed, untreated pancreatic cancer to 50 age-matched people with a non-cancerous pancreatic condition. They aim to ident…

This observational study is investigating whether certain blood markers and gut microorganisms can help identify people with chronic pancreatitis who are at higher risk of developing pancreatic cancer. Researchers will compare healthy individuals, those with chronic pancreatitis,…

This study looks at whether a new blood test can find tiny bits of tumor DNA left behind after pancreatic cancer surgery. About 30 adults who had their cancer removed will give blood samples at three key times over six months. The goal is to see if this test can detect remaining …

This study enrolls 275 people with advanced solid tumors to test a new approach: using a rapid, detailed analysis of each patient's tumor and immune system to guide treatment choices. The goal is to improve the success rate of immunotherapy, which currently helps only 20-30% of p…

This trial investigates whether a special type of MRI scan, called DCE-MRI, can better assess how well chemotherapy is working in people with borderline resectable pancreatic cancer. Participants will receive standard chemotherapy and undergo DCE-MRI scans along with regular imag…

This trial looks at whether keeping or removing a drainage tube (PTCD catheter) during pancreatic surgery leads to fewer complications. About 100 patients with jaundice from tumors will be randomly assigned to one of two groups. The main goal is to see which approach reduces seri…

This study is developing an artificial intelligence system that measures changes in total tumor volume from CT or MRI scans to see if it can predict survival better than the current standard method, which measures just a few tumors. Researchers will analyze data from about 6,000 …

This study collects blood samples from people with cancer or at high risk for cancer to create a large, well-organized repository for research. The goal is to provide scientists with a valuable resource to study cancer through liquid biopsies, which may lead to better detection a…

This study uses advanced 4D MRI scans to measure blood flow and heart function in adults with heart disease or cancer. Researchers aim to see if these detailed images can help predict how these diseases will progress. The study involves 1,000 participants who are already schedule…

The EXPAND study is a research project that will enroll 440 adults with and without pancreatic conditions to understand why type 2 diabetes varies so much from person to person. Researchers will collect data on metabolism, genetics, and pancreas health to identify distinct diabet…

This study is testing a new approach to personalize cancer treatment for people with colorectal or pancreatic cancer. Researchers will take a small sample of a patient's tumor, grow it in the lab, and test different drugs on it to see which one works best. The goal is to see if t…

This study tracks how the experimental drug AZD1390 moves through and leaves the body after a single dose. It involves about 8 adults with advanced solid tumors who are not currently on active cancer treatment. By using a tiny radioactive label, researchers can measure the drug i…

This study looks at why some patients develop blood clots after pancreatic surgery that also involves removing a piece of a major vein. Researchers will collect information from over 1,000 patients across many hospitals to see how surgical techniques and blood-thinning medication…

This study will follow 800 people, including those with chronic pancreatitis, pancreatic cancer, and healthy volunteers, to learn why some pancreatitis patients later get pancreatic cancer. Participants give blood samples and health info; some may also provide tissue samples. Res…

This study looks at how removing part or all of the pancreas changes blood sugar control in adults who already have diabetes and need pancreatic surgery. Researchers will track 408 patients over time to see if diabetes gets worse depending on how much pancreas is removed. The goa…

This study is a registry that collects medical information and biological samples from up to 100,000 people with gastrointestinal cancers, such as pancreatic or colorectal cancer. No new treatments or drugs are given. The goal is to gather real-world data to help researchers answ…

This study will follow about 579 adults who need surgery to remove part or all of their pancreas but do not have diabetes before the operation. Researchers want to see how often new diabetes develops after surgery and whether the amount of pancreas removed changes that risk. The …

This study looks at whether it is safe to give patients their own salvaged red blood cells back during surgery for pancreatic cancer. About 40 adults will take part, and researchers will track infections and other complications within the first week after surgery. The goal is to …

This study aims to see if using a patient's genetic signature to choose chemotherapy can improve outcomes for people with borderline resectable pancreatic cancer. About 367 participants will receive standard chemotherapy, and researchers will track how long they live without majo…

This early-stage study looks at whether taking oral paclitaxel with encequidar on an empty stomach or after a meal changes how much drug gets into the body. About 46 adults with advanced solid tumors (like breast, lung, or stomach cancer) will take the drugs in different sequence…

This study looks at whether tumor DNA found in blood or peritoneal fluid can predict the spread of digestive cancers (stomach, colon, pancreas) to the lining of the abdomen. Researchers will follow 300 patients with early-stage tumors to see if those with positive DNA markers are…

This study tests whether using MRI scans to plan radiotherapy is better than using CT scans alone. Researchers will work with up to 150 cancer patients and 15 healthy volunteers to see if MRI can make treatment more precise and reduce side effects. The goal is to improve how tumo…

This study aims to find biological markers in the blood, immune system, and gut microbiome that can help doctors choose the best treatment for people with advanced pancreatic cancer that cannot be removed by surgery. Researchers will collect blood and stool samples from 140 parti…

This study looks at whether people with pancreatic cysts (IPMN) also have trouble digesting food due to poor pancreatic function. Researchers will follow 600 adults to see if this digestive problem is linked to cyst growth or cancer risk. The goal is to find a simple test that he…

This study looks at whether a polygenic risk score—a measure based on many small genetic variations—can help predict who might develop pancreatic ductal adenocarcinoma (PDAC). Researchers will compare the genetic profiles of about 1,140 people with and without the disease. The go…

This study checks if a short questionnaire called G8 can correctly identify frailty in people aged 70 and older with solid tumors. Researchers will compare the G8 results with a full geriatric assessment in 150 patients. The goal is to see if the G8 tool works well for Portuguese…

This study looks for biological markers in tumor tissue and blood that may be linked to anxiety and depression in people with solid tumors. Researchers will combine psychological assessments with lab tests to better understand these emotional struggles. The goal is to improve ear…

This study looks at a new way to detect cancer cells in the portal vein blood of people with pancreatic cancer. The goal is to see if these cells can warn early if the cancer comes back or spreads. The study will involve 20 participants and uses a special ultrasound-guided proced…

This study looks at whether draining a blocked bile duct before surgery for pancreatic cancer changes the tumor's behavior or patient survival. Researchers will review medical records of 90 patients who had their pancreatic tumor removed over 8 years. They will compare those who …

This study looks at whether doing broad gene testing early, instead of later, helps find more effective treatments for people with advanced pancreatic, liver, or triple-negative breast cancer. About 360 adults with poor-prognosis cancers will be randomly assigned to early or stan…

This study will watch how doctors use a special camera (endoscopic ultrasound) to diagnose suspected pancreatic or bile duct diseases in 2500 adults across Lombardy, Italy. The goal is to see how accurate the procedure is, how safe it is, and how quickly patients get a final diag…

This observational study will enroll 185 people with metastatic pancreatic cancer to see if analyzing tumor genes and lab-grown organoids can predict which standard chemotherapy regimens work best. Researchers will compare predicted drug sensitivity to actual patient outcomes. Th…

This observational study will measure how well the body breaks down blood clots in 150 cancer patients (with blood cancers or solid tumors) who also have clotting issues. Researchers will take extra blood samples during routine care to look for markers that might predict bleeding…

This study looks at how the bacteria in the gut and mouth relate to nutrition in 150 adults with digestive cancer starting chemotherapy. Researchers will collect stool and saliva samples, along with questionnaires and tests, before and after the first chemo cycle. The goal is to …

This study will test if measuring hand grip strength during clinic visits is practical and useful for adults with pancreatic cancer. Fifty participants will squeeze a handheld device and fill out well-being questionnaires alongside their regular care. Researchers want to see if c…

This study creates a registry of 500 cancer patients receiving immunotherapy to better understand and manage immune-related side effects (irAEs). Researchers will collect data on who gets these side effects, how they present, and what treatments work best. The goal is to improve …

This study aims to adapt a questionnaire called PROFFIT, originally developed in Italy, to measure financial toxicity (the financial burden of cancer treatment) in Turkish patients. Researchers will enroll 320 adults with cancer who have received treatment in the last three month…

This observational study looks at how immune checkpoint inhibitors (a type of cancer immunotherapy) affect ovarian function and fertility in women aged 18-38 with solid tumors. Researchers will collect blood and stool samples before and during treatment to measure hormone levels …

This study will follow 200 adults undergoing surgery for liver, esophagus, or pancreatic cancer. Researchers want to see how patients' expectations before surgery relate to their pain, painkiller use, and recovery afterward. The goal is to learn how to better manage pain and impr…

This study will observe 300 people with advanced lung or gastrointestinal cancers who receive adebrelimab combined with other treatments. Researchers will track side effects and how well the cancer responds. It is a real-world study, meaning it watches what happens in regular med…

This study will test a new automated blood test that measures how well a patient's T-cells (immune cells) are working. The goal is to see if the test results match how well the cancer responds to standard immunotherapy drugs like anti-PD1 or anti-CTLA4. The study will include 100…